FibroBiologics (FBLG) vs InMed Pharmaceuticals (INM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
FibroBiologics is the larger company by market cap ($8.2 million vs $7.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | INM |
|---|---|---|
| Share price | $1.19 | $1.36 |
| Market cap | $8.25M | $7.47M |
| 1-day change | +6.86% | +2.26% |
| EPS (TTM) | $-5.01 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.98 | $2.40 |
| 52-week low | $0.62 | $0.575 |
| Distance from 52-week high | -88.12% | -43.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +954.23% | — |
| Average volume | 204.44K | 914.23K |
| Shares outstanding | 6.96M | 5.49M |
| Employees | 15 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About InMed Pharmaceuticals
INM stock →InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
FBLG vs INM FAQ
Which is bigger, FibroBiologics or InMed Pharmaceuticals?
FibroBiologics (FBLG) is larger, with a market capitalization of $8.25M compared with $7.47M for InMed Pharmaceuticals (INM).
Are FibroBiologics and InMed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.